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Abstract 
At least 30 million people worldwide carry a diagnosis of atrial fibrillation (AF), and 
many more suffer from undiagnosed, subclinical or “silent” AF.  AF-related 
cardiovascular mortality and morbidity, including cardiovascular deaths, heart failure, 
stroke, and hospitalizations, remain unacceptably high, even when evidence-based 
therapies such as anticoagulation and rate control are used. Furthermore, it is still 
necessary to define how best to prevent AF, largely due to a lack of clinical measures 
that would allow identification of treatable causes of AF in any given patient. Hence, 
there are important unmet clinical and research needs in the evaluation and 
management of AF patients. 
The ensuing needs and opportunities for improving the quality of AF care were 
discussed during the 5th Atrial Fibrillation Network (AFNET)/European Heart Rhythm 
Association (EHRA) consensus conference in Nice on 22nd and 23rd January 2015.  
Here, we report the outcome of this conference, with a focus on:  
1. Learning from our “neighbours” to improve AF care 
2. Patient centred approaches to AF management 
3. Structured care of AF patients 
4. Improving the quality of AF treatment 
5. Personalization of AF management 
This report ends with a list of priorities for research in AF patients. 
 
Key words 
Atrial fibrillation, outcomes, quality of care, research, rate control, antiarrhythmic 
drugs, catheter ablation, anticoagulation, cardiovascular risk, bleeding, research 
priorities 
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Introduction 
At least 30 million people worldwide carry a diagnosis of atrial fibrillation (AF) 1, and 
many more suffer from undiagnosed or “silent” AF.  Oral anticoagulation can prevent 
the majority of AF-related strokes 2, but does only partially mitigate the burden of AF 
that affects patients, their families, and society 3: AF-related cardiovascular mortality 
and morbidity, including cardiovascular deaths, heart failure, stroke, and 
hospitalizations, remain unacceptably high. 3, 4 The prevalence of diagnosed AF has 
increased in Europe in recent years 5, 6, due to better awareness of AF, earlier and 
systematic diagnosis of AF, and an increase in the conditions that predispose to 
developing AF. 7  In fact, we have to expect that 2% or even 3% of the populations in 
Europe and in other parts of the world suffer from atrial fibrillation 1, 8, including those 
with silent AF 1, 8-10: Clearly, this alarming increase calls for better ways to prevent AF: 
We are not able to prevent AF, largely due to a lack of clinical measures that would 
allow identification of treatable causes of AF in any given patient. Hence, there are 
important unmet needs in the evaluation and management of AF patients. 
The ensuing needs and opportunities for improving the quality of AF care were 
discussed during the 5th Atrial Fibrillation Network (AFNET)/European Heart Rhythm 
Association (EHRA) consensus conference in Nice on 22nd and 23rd January 2015.  
Here, we report the outcome of this conference, with a focus on:  
1. Learning from our “neighbours” to improve AF care 
2. Patient centred approaches to AF management 
3. Structured care of AF patients 
4. Improving the quality of AF treatment 
5. Personalization of AF management 
This report ends with a list of priorities for research in AF patients. 
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1. Learning from our neighbours.  
Health care systems, like political systems, develop and “grow” into different shapes in 
different jurisdictions. Some developments are well suited for patient-centred care 
and/or may be more efficient compared to others. Controlled trials comparing 
different ways to deliver AF patient care 11, 12 and regional differences in AF 
management highlight opportunities to improve outcomes in AF patients. 13, 14 
Systematic comparisons of health care systems are a useful tool to inform change in 
health care systems. 15 In addition, informal exchange of health care organisation can 
benefit health care professionals and patients. Despite differences in background risk, 
complications of AF and treatment strategies, the goals of care remain the same: 
stroke prevention, reduction in cardiovascular complications and amelioration of 
symptoms. Universally, these issues can be addressed by thoughtful consideration and 
administration of anticoagulant therapy, rate control and rhythm control therapy, and 
appropriate management of concomitant cardiovascular conditions. 
Each country has a unique variety of regional or local organizations that deliver health 
care. In some countries, healthcare plans (e.g. Medicare in the US) are in place for 
some populations but not for others, whilst in other countries almost universal 
healthcare coverage provides equal access to specialist and generalist care (e.g. 
Austria, Belgium, Germany, the Netherlands, Scandinavia, the UK, and others). 
Private purchase of medications and healthcare services is the only means to access 
health care in some other areas of the world. In some jurisdictions, health care is 
organized centrally or even directly by state agencies, in others it is managed by 
regional authorities or offered by units that compete for patients and payment. In 
addition, the care of AF patients differs markedly, as reflected by simple indicators 
such as the responsible health care professional (Table 1).  
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Observational studies suggest that the prevalence of AF may be higher in Caucasians 
than in persons of African or Asian ethnicity. 16 Similarly, differences in stroke risk in 
patients with diagnosed AF have been found, e.g. higher stroke rates in China 
compared to Europe in patients at similar stroke risk based on scoring systems. 17, 18 
Such disparity likely reflects differences in the definition of cardiovascular diseases, 
access to diagnostic procedures, and differences in the management of cardiovascular 
diseases including antihypertensive treatment, heart failure management, 
anticoagulation, 13 or rhythm control interventions.14  Differences in “customary” 
treatment patterns and different organisation of health care systems can furthermore 
explain the variation in use of evidence-based AF therapies such as oral 
anticoagulants, 19 in the quality of INR control or in the use of catheter ablation.  Such 
differences are not compatible with the principle of equal access to evidence-based AF 
management for all patients and may lead to increased cost in the long-term.  
In summary, the care offered to AF patients is different in different countries and 
regions, at times resulting in variations in quality of care. There is a huge opportunity 
to improve AF care by exposing these differences and identifying the factors that drive 
high quality diagnosis and treatment of AF. International organisations such as the 
European Society of Cardiology (ESC) should contribute to the identification of these 
differences, and coordinate the discussions that are needed to improve diagnostic and 
therapeutic pathways by learning from our neighbours. 
We recommend a continued professional dialogue about the optimal infrastructure 
and type of AF care, based on comparable data on type of AF care, outcomes, and 
resource use in different health care settings to allow improvement of existing AF 
services. 
We recommend a policy of identifying role models of excellent AF care for wider 
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implementation. 
 
2. Patient centred approaches to atrial fibrillation management 
Shared decision making with informed patients. Shared decision making and 
active involvement of patients in chronic care is a principle that should guide most 
relations between patients and physicians. It seems very suitable for the management 
of AF. Recent clinical guidelines have stressed the importance of integrating patient 
preferences into AF management. 20-23 This reflects a broader move in society to 
educate and inform patients and communities, thus empowering them to contribute 
actively to decisions about their care.  The 2012 ESC AF guidelines have already 
emphasized the need for shared decision making in the management of AF. 24  
As stated by Seaburg et al 25, “the goal of shared decision making [in the management 
of patients with AF] is to increase the likelihood that patients will receive the care 
that they need in a manner consistent with the best available research evidence and 
their values and preferences”.  It requires a change away from traditional 
“paternalistic” models of treatment decisions to a model integrating medical facts into 
an open discussion with the patient who contributes his or her own values and 
preferences.  As a result, patients will be appropriately informed about their disease, 
its potential progression and complications, and the various treatment options.  AF 
seems ideally suited to shared decision making given the range of alternative 
diagnostic and treatment options that are available.  This is particularly true when 
there is clinical equipoise relating to a decision affecting the patient in markedly 
different ways, such as the choice between antiarrhythmic drugs or catheter ablation 
for initial rhythm control of AF.  The main aim is to empower the patients to be 
appropriately informed about all aspects of their health, wellness and disease state, 
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ultimately improving the outcome of care. Active participation of patients is needed to 
make life style changes that will improve outcomes and quality of life in AF patients 
(Table 2A) and to ensure adherence to therapy. However, it is important to gauge the 
patient’s desire for their degree of involvement in treatment decisions as some patients 
may prefer the doctor to make treatment recommendations while other prefer shared 
decision-making. 
 
Patient reported outcomes. Patient reported outcomes (PRO) are defined as “any 
report of the status of a patient’s health condition that comes directly from the patient, 
without interpretation of the patient’s response by a clinician or anyone else”. 26  PROs 
include assessment of health-related quality of life and symptoms.  PROs may be used 
in a number of applications 27 to provide the patient voice within AF care.  In a routine 
clinical setting, quality of life or symptom questionnaires may be used to provide a 
standardized estimation of a patient´s well-being to health-care providers. Although 
most instruments have been validated as paper questionnaires, completed by the 
patient or with the help of a health care professional, they are suitable for digital, semi-
automated or remote assessment of patients. 28 In the future these data may be used at 
an individual level to identify patients with deteriorating symptoms or aggregated to 
provide a quality measure, Although the use of PRO instruments in AF patients is in its 
infancy, these data are likely to evolve further and may develop into a quality measure 
in the future. 29-31 
 
Shared decision making in the care of AF patients. Once AF is diagnosed, 
individual assessment should identify the modifiable risk factors (e.g., arterial 
hypertension, diabetes mellitus, alcohol consumption, obesity, smoking, sleep apnoea 
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and concomitant cardiovascular diseases) which are found in approximately 60% of 
populations with AF. 32  Such precipitating factors may be modified by changes in 
lifestyle 33, 34, while an inherited predisposition to AF cannot be modified.  Since AF is 
a heterogeneous disease with respect to its aetiology, pathophysiology, mechanisms, 
clinical presentation, natural history 35, 36 and outcomes, patients are entitled to 
comprehensive information on the causes, manifestations, and complications of AF.  
The concept of different types of AF reflecting the main pathophysiological drivers of 
the arrhythmia seems suitable for this conversation 7 and needs to be supplemented by 
information on the complex interaction of disease-related factors in the shared 
decision making process. Patients with AF need adequate and understandable 
information about the main complications, such as stroke, cognitive impairment, heart 
failure and sudden death.  They should recognize signs of stroke (new-onset 
neurological deficit) and heart failure (shortness of breath) and the need for 
immediate medical attention when such symptoms develop or quickly worsen.  
Information technology can provide such information in a tailored way via interactive 
electronic educational material (e.g. www.afibmatters.org or http://www.atrial-
fibrillation-network.eu/en/home or www.afassociation.org.uk). This will require time and a 
willingness to explain the information in a language that the patient understands. 
These resources seems well invested to enable the patient to understand and execute 
the agreed management plan. 
We recommend the involvement of all AF patients in the major decisions about their 
care, and to enhance the publicly available information on AF, its complications, and 
the therapeutic options. 
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3. Structured care of AF patients 
Evidence-based management of AF patients. Many aspects of AF management 
are informed by clear evidence, which is reflected in largely overlapping (but with 
some worrying differences) international guidelines on treatment of underlying 
cardiovascular conditions, anticoagulation, rate control, and rhythm control. 20, 21  
There are multiple treatment modalities, but also many causes of AF, drivers of AF-
related complications, and reasons for impaired patient well-being.  The profile and 
treatment needs of AF patients change over time, and frequently require in-patient 
hospital care when managed in current approaches. 37, 38  Hence, adequate 
management of AF patients is complex.  It requires a structured approach. 39, 40  Such 
AF care should ensure that evidence-based therapy is offered to all AF patients, and 
that follow up and repeated evaluation are sufficient to maintain adherence to agreed 
management principles. Integrated, multidisciplinary care of AF patients, supported 
by information technology and patient education, can help to avoid AF-related 
complications and hospital stays according to recent randomized trials, thereby 
reducing the burden of AF to patients and decreasing the cost of care. 41 The 
organization of care will differ locally (see section 1) and local solutions will need to be 
developed to define a good model of care. 
We suggest the development of structured, patient-centred care plans for all AF 
patients, based on structured initial evaluation and guided by risk profiling and 
symptom assessment (Table 2). 39  Interdisciplinary, dedicated AF services which 
also incorporate lifestyle interventions are likely to facilitate such a structured, risk-
based, patient-centred care model. 41 
We recommend the development of integrated and structured approaches to AF care 
led by interdisciplinary teams to improve the quality of AF care. 
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3. Improving the quality of AF treatment 
Patients are entitled to high quality care that is safe, effective, and accessible. While 
the medical literature has traditionally focussed on the best way of caring for patients, 
it is important to define minimal standards of good care for AF patients. Such 
standards would ideally be developed and endorsed with wide input from global 
stakeholders. 
We recommend that quality standards are defined and monitored in AF care. EHRA, 
AFNET and similar organisations in other parts of the world should play a central 
role in the further definition and dissemination of such criteria, and in linking these 
to outcomes. The following sections (4.1 - 4.4) outline quality criteria, which are 
summarized in Table 3.1-3.3. 
  
4.1 Timely diagnosis of atrial fibrillation 
Many people, especially those who are older and have concomitant cardiovascular 
conditions, suffer from undiagnosed, “silent” AF. The prognosis of untreated 
asymptomatic atrial fibrillation is characterized by a high risk of stroke and death 
which can be reduced by appropriate oral anticoagulation. 42  Screening for unknown 
AF and initiation of anticoagulation has the potential to prevent strokes in patients 
with undiagnosed AF, but has so far mainly been evaluated in physician offices, where 
pulse palpation followed by 12-lead ECG recording seem cost effective for AF 
screening.43, 44 A recent systematic review 45 demonstrated that unknown AF would be 
detected in 1.4% of the population aged ≥65 on a single screening whether in a clinical 
or community setting. Pulse palpation is universally available to an educated 
population. Novel technologies which allow easy cardiac rhythm assessment by lay 
persons and patients, either by pulse irregularity (oscillometry 46 or smart phone 
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camera 47) or by analysis of an ECG rhythm strip 48-51, are now readily available and 
offer better, less costly methods for more  effective and more broadly-based AF 
screening. A number of studies have explored population or clinic screening using 
hand-held single-lead ECG devices. 48-50 An economic analysis showed that if an AF 
screen with these devices at a single time point was extended to the population aged 
65-84 years, it would be cost-effective for stroke prevention. 49 Community pilot 
screening studies suggest that the criteria for widespread screening over age 65 are 
now met, 52 but the precise implementation method would need to fit with the country-
specific health care system. 
Silent AF first presenting with ischaemic stroke accounts for at least 10% of all 
ischaemic strokes. 53-56, and widespread screening could substantially reduce this 
figure.  A systematic review found that an additional 11.5% of survivors will have 
paroxysmal AF which remains undetected by current ECG monitoring practices, but 
may be detected by prolonged non-invasive or invasive ECG monitoring, although the 
available studies are heterogeneous. 57  More recently, two randomised trials of either 
30 day external monitors 10 or 1- 3 years of implantable cardiac monitors 58 
demonstrated an even higher detection rate of AF, albeit in a subgroup of stroke 
survivors with “cryptogenic” stroke. Some form of prolonged monitoring after 
ischaemic stroke should now become the standard of care 59, and offered by a high 
quality AF service. Ongoing randomized multicentre studies such as MonDAFIS 
(NCT02204267) will determine whether the detection of “silent” AF after acute 
ischemic stroke will change long term management in stroke survivors. 
We recommend the establishment of more widespread screening programmes for 
persistent and paroxysmal AF in those over age 65, and in populations at risk, 
particularly survivors of ischaemic stroke. 
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4.2 Defining and improving the quality of stroke prevention 
The majority of ischaemic strokes in AF patients are caused by AF, and a substantial 
proportion of those “cardio-embolic” strokes can be prevented by oral anticoagulation. 
Aspirin is not effective in preventing strokes in AF. Nonetheless, underuse or 
premature termination of therapy with oral anticoagulants is still common. 60-65  
Although non-vitamin K antagonist oral anticoagulants (NOAC) are easy to handle and 
offer the promise of improved efficacy and safety compared to vitamin K antagonist 
(VKA) treatment 2, 66, there is still a substantial underuse of oral anticoagulation in AF 
patients in the “NOAC era”. 67, 68  While anticoagulation therapy needs to be paused 
when patients actively bleed, absolute contraindications to long-term anticoagulant 
treatment in AF patients are rare, e.g. severe bleeding without treatable underlying 
cause in critical organs.  The bleeding risk of anticoagulant use in elderly patients, in 
patients with cognitive dysfunction, or in those with frequent falls or frailty is often 
overestimated and should usually not preclude the use of anticoagulants. 69, 70  
Oral anticoagulants need to be taken consistently.  The best evidence for this stems 
from analyses of the time of patients treated with VKA within and below the 
therapeutic range 71, but it seems reasonable to suggest that regular intake of relatively 
short half-life NOACs is even more important for successful stroke prevention. 65, 72 
Although adherence to therapy is currently not measured systematically in clinical 
practice, the outcomes of recent observational data-sets replicate the findings in phase 
III trials of NOACs . 66, 73  Dedicated interventions to enhance adherence to therapy are 
currently being evaluated e.g. AEGEAN (NCT01184350). 74, 75 Permanent withdrawal 
of anticoagulation therapy is associated with cardiovascular complications. Re-
initiation of anticoagulation after a bleeding event is often possible and clinically 
justified.  Difficult decisions, including the discontinuation of anticoagulation, should 
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be taken by multidisciplinary teams involving AF, anticoagulation, stroke specialists as 
well as the patients to adequately balance the risks and benefits of continued 
anticoagulation. 
Limited reimbursement of NOACs is an important driver of inequality in care of 
patients with AF. 68 This group advocates access to NOACs for all AF patients in need 
for oral anticoagulation as an initial therapy option. 66, 73, 76, 77 When this is not deemed 
feasible, clinical estimates for the likelihood to achieve good anticoagulation with VKA 
could be considered to identify patients who can be treated with VKA. 73, 78 
We recommend the following steps to improve stroke prevention in AF patients 
1. All AF patients in need of oral anticoagulation should have access to NOAC 
therapy, or to VKA therapy, if NOACs therapy is not feasible. 
2. We recommend a structured follow-up for all anticoagulated AF patients to 
remind the patient of the need for AF treatment and to increase adherence and 
persistence to therapy. 40, 79 
3. AF patients who suffer a stroke should be acutely managed in specialized stroke 
units. 80 
 
4.3 What is effective rate control? 
 The goal of rate control therapy of AF is to reduce patient symptoms and prevent a 
tachycardia-related reduction in myocardial function.  While these treatment goals can 
be achieved with a lenient rate control approach in some patients 81, others may 
require stricter rate control, such as those with heart failure or persistent symptoms. 
21, 22  The effectiveness of rate control therapy should be assessed at regular intervals in 
AF patients as part of integrated AF management.  Adjustments to rate control 
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medication seem necessary in many patients 60, 82, and all AF patients need systematic 
follow-up to allow such adjustments over time. Such assessment will require analysis 
of a conventional 12-lead ECG, Holter consideration of patient symptoms and 
preferences, and repeated assessment of left ventricular function (especially when 
symptoms worsen).  The optimal therapy for achieving rate control requires further 
research. 83, 84 Until the results of such research are available, it will be difficult to 
define quality indicators for effective rate control therapy in addition to the simple 
statement that resting heart rate should be < 110 bpm. In patients who remain 
symptomatic on such a lenient rate control therapy, it may be worthwhile to control 
rate during exercise, and/or to aim for a lower resting heart rate.  
 
4.4 Improving quality of rhythm control therapy  
Defining quality in AF ablation. The evidence underpinning the use of catheter 
ablation to maintain sinus rhythm in symptomatic AF patients has mainly been 
generated in recognized regional, national, or international centres of 
electrophysiological excellence.  As AF ablation is being offered to more patients, and 
hence AF ablation services are established in more and more centres, recruiting and 
training of electrophysiologists and maintaining a high quality of AF ablation 
procedures develops into a key issue. It is recognized that there is a need to define and 
measure quality, both in terms of AF ablation operators and institutions offering AF 
ablation.  Catheter ablation of AF, especially isolation of the pulmonary veins, is now a 
standardized procedure that has become part of routine clinical care. 24, 85, 86. Thus, a 
set of variables to define both a qualified operator and a quality AF ablation centre is 
proposed (Table 3.3).  Using these criteria, systematic assessment of the AF ablation 
operators and of AF ablation centres can be undertaken to ensure their quality, and to 
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study the validity and the clinical usefulness of these criteria. This process should be 
led by professional organisations such as EHRA or Heart Rhythm Society (HRS). 
 
Hybrid rhythm control therapy. It is well recognized that catheter ablation will 
not completely eliminate AF in many patients. 87, 88 It is in this context that we discuss 
the concept of “hybrid therapy” for AF (ablation plus antiarrhythmic drugs).  Hybrid 
therapy, defined as the use of antiarrhythmic drug therapy more than 3 months 
following an ablation to reduce symptoms and/or episodes of AF, is a common 
therapeutic concept in AF patients. 89, 90 While it is common practice to stop 
antiarrhythmic drugs a few weeks or months after restoration of sinus rhythm by 
catheter ablation 91 or cardioversion 92, the result is an excess in AF recurrences 
compared to continued antiarrhythmic drug therapy 91, 92  Hence, some patients may 
be advised and/or may prefer to continue antiarrhythmic drug therapy after ablation 
of AF, especially when the therapy is well tolerated, integrating patient preferences, 
the perceived risk of recurrence, and the risk of therapy. 93 
 
Repeat ablation or antiarrhythmic drug therapy after AF ablation? Many 
patients who undergo an initial AF ablation will continue to experience symptomatic 
AF once antiarrhythmic drugs have been discontinued. 85, 89  Decisions to perform a 
repeat ablation should only be done once recurrence of AF has been documented and 
follow the same process used to decide on the initial AF ablation.  This process 
involves shared decision making based on a consideration of safety and efficacy of 
repeat ablation, discussion of all treatment options including antiarrhythmic drug 
therapy and acceptance of AF (“rate control only”), and should integrate patient 
preferences.  Hereby, the patient has a better appreciation of what the procedure 
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involves, and the electrophysiologist has more knowledge about the procedural details, 
including risk and the potential extent of re-ablation. Atrial tachycardias may be better 
amenable to re-ablation than AF. Some patients will prefer a trial of antiarrhythmic 
drugs rather than repeat ablation. 
We recommend systematic collection of information on centre and operator quality, 
based on simple quality indicators and procedural complications (Table 3.3), from all 
AF ablation centres. 
We recommend further research into the best rhythm control therapy in patients 
with recurrent AF after AF ablation. 
 
5. Beyond the present state of the art: Personalized AF management 
A broad range of different cellular and molecular mechanisms underlie AF and are 
modified by environmental factors. 94-96  Thus, the manifestation, progression and 
outcome of disease will vary between these subtypes of AF, consistent with clinical 
observations.7 Furthermore, the clinical differentiation between “paroxysmal” and 
“persistent” AF may be poor, suggesting that this differentiation is not reflecting 
different biology. 97 Clinical conditions that are associated with AF and AF-related 
complications may vary substantially by AF aetiology, but will overlap.  To investigate 
the development of mechanism-oriented therapy of AF, prior consensus conferences 
suggested a pathophysiological classification of AF types. 7  The precise identification 
of AF mechanisms would ideally involve assessment of atrial tissue.  As this is 
inherently difficult to obtain, blood (or possibly imaging) markers that correlate with 
atrial pathophysiology, could indicate whether major molecular mechanisms of AF are 
present in a given patient.  Cardiac imaging modalities such as echocardiography, CT, 
or magnetic resonance imaging give a relatively detailed view of atrial size and to some 
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extent of atrial structure. They usually require specialised equipment and expertise for 
interpretation, and have been discussed in a recent review 7. The existing biomarkers 
for AF were therefore reviewed with a view to utilising them for the classification of AF 
patients into different types. 
Unfortunately, many biomarkers that have been evaluated in AF patients identify 
abnormal cardiac or inflammatory states, rather than reflecting atrial pathology. 
Natriuretic peptides, in particular B-type natriuretic peptide (BNP), cannot 
differentiate between underlying or concomitant cardiovascular conditions and 
comorbidities.  Elevated BNP is associated with incident AF, and BNP is correlated 
with disease burden, e.g. frequency and duration of AF episodes and overall cardiac 
abnormality.98  Its predictive ability for new onset AF in community cohorts is strong, 
but improvement in C-statistic and reclassification remain modest. 99, 100  N-terminal 
pro-BNP is also strongly and independently associated with stroke and mortality in 
patients with AF. 101 
C-reactive protein may be considered for general cardiovascular risk assessment when 
treatment decisions based on conventional risk scoring are uncertain. 102  Although 
modification of C-reactive protein concentrations, e.g. by statin treatment may alter 
AF risk 103 , Mendelian randomization, i.e. a correlation of genetic determinants of 
CRP levels and their association with AF, suggests that it is unlikely that C-reactive 
protein per se causes AF. 104  Consequently, the power of CRP to identify patients with 
AF is low. 99, 100 
Similarly, markers of impaired kidney and bone marrow function such as glomerular 
filtration rate, cystatin C, or low hemoglobin have been associated with many aspects 
of AF pathophysiology. 105  They represent aging, general health status and comorbid 
conditions that affect AF incidence and prognosis rather than intrinsic AF 
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mechanisms. While the combination of these markers of disease can slightly improve 
the prediction of incident AF 99, 100 , or complications of therapy (e.g. bleeding on 
anticoagulants), the value of such general biomarkers for personalized management of 
AF needs to be established. It seems unlikely that these markers can discriminate 
different subtypes of AF in the near future. 
 
Common genetic variants. Genetic variation is fairly stable over a life course, 
independent of environmental changes and may help to define AF subtypes.  In rare 
monogenic AF, a single mutation determines the disease phenotype (e.g. long QT 
syndrome or an inherited cardiomyopathy, but also in familial AF 106, 107).  Common 
genetic polymorphisms correlate with the risk of AF development and risk of stroke, 
and predispose to recurrences of AF on antiarrhythmic drugs 108 or ablation success. 
109  About a third of all AF patients carry common gene variants that predispose to AF. 
110, 111  In general, every single nucleotide polymorphism (SNP) only carries a small 
relative risk, but they can be combined to generate more precise information. 111, 112  
Genetically determined subtypes of AF in the community have not yet been 
formulated.  Future in-depth analysis of genetic information collected in large 
consortia will provide additional information on the genetic underpinnings of AF, 
including very many SNPs.  Furthermore, the molecular mechanisms conveying AF 
risk in carriers of the AF-related genetic variants may unveil novel “atrial specific” 
disease pathways and biomarkers, including altered epigenetic or microRNA related 
pathways. 113-118 The practical consequences of these findings need to be determined 
and tested in controlled trials. 
 
The search for atrial-specific biomarkers. The increasingly broad availability of 
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novel “big data” technologies will provide access to blood and tissue for largely 
unbiased “omics” interrogation.  Omics data including genome transcriptome, 
proteome and metabolome information will reveal intermediate phenotypes and 
disease patterns in AF.  These analyses have the potential to identify promising new 
AF biomarkers. The information derived from different clinical and molecular sources 
then needs to be combined to identify new biomarkers or marker signatures of clinical 
relevance.119  
Novel biomarkers will need to be able to identify a group of AF patients (or 
populations at risk for AF) who respond well to a given therapy and/or who show a 
distinct course of disease, e.g. in terms of AF progression or for complications of AF.  
Subsequently, proof of concept and prospective controlled testing need to demonstrate 
feasibility and cost effectiveness. 
The overall success of future biomarker studies will rely crucially on two interrelated 
issues: the establishment of distinct AF phenotypes and rigorous validation of 
biomarkers e.g, as recently suggested by the Transparent Reporting of a multivariable 
prediction model for Individual Prognosis Or Diagnosis (TRIPOD) investigators. 120  
Current biomarker studies are limited by the crude AF phenotype definition that 
impairs specific associations.  On the other hand, biomarkers and biomarker 
signatures may largely enhance the differentiation of AF subtypes and their optimal 
management.  Existing and emerging biomarkers and AF subtypes will then need 
rigorous validation and prospective testing. 
 
ECG parameters. The ECG is a widely available diagnostic test in many health care 
settings. Furthermore, emerging technology will give patients and citizens 
unsupervised access to ECG recordings. Several ECG parameters can be used to detect 
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patients at risk for AF. The PR interval has a clear genetic trait 121, 122 and a prolonged 
PR interval is associated with an increased the risk of prevalent AF in populations. 123-
125  Direct electrocardiographic contact mapping studies in patients undergoing open-
chest surgery have indeed demonstrated that a progressive structural remodeling 
process is reflected in more complex atrial activation patterns 126, 127 which may 
promote recurrent AF 128-130. The complexity of the AF activation pattern may be 
indirectly measured by time domain (F-wave analysis, principal component analysis, 
sample entropy) and frequency domain (dominant frequency, organization index of 
power spectrum, spectral entropy) parameters. 131 Such quantifiable parameters of “AF 
complexity” have been evaluated as markers for recurrent AF in patients receiving 
rhythm control therapy (cardioversion, antiarrhythmic drug therapy, or catheter 
ablation). 132, 133 Sufficiently powered studies using standardized technology are 
needed to determine the clinical value of ECG analyses during AF to differentiate 
different types of AF. 132 
 
We recommend performing properly powered genomic, genetic and biochemical 
analyses in controlled trials. 
We recommend using existing large biosample collections to identify atrial-specific 
biomarkers. 
We recommend research into clinical parameters that can differentiate different 
“aetiologic types” of AF.
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6. Research priorities in the next five years 
Based on the challenges in understanding and eliminating the inequalities and barriers 
that prevent optimal care of AF described above, we have outlined the priority 
research needs: 
1. Prospective studies evaluating the prognostic value of modern rhythm control 
therapy are fortunately underway and should be completed as soon as possible. 
2. Prospective studies are needed to determine the most effective strategy for AF 
detection in populations and in patients at risk for AF and stroke, including the 
methods of detection, implementation and cost effectiveness. 
3. Evaluation of integrated and structured care approaches compared to current 
care models has immense potential to improve quality of AF patient care and is 
essential to make these useful in clinical practice. 
4. Definition of the optimal patient reported outcomes to capture AF-related 
symptoms and patients’ experiences of AF, and the development and adoption of 
methods to ensure optimal PRO assessment and reporting from AF trials. 
5. Evaluation of new parameters (e.g. blood biomarkers, ECG parameters, etc.) to 
refine anticoagulation decisions in patients with an intermediate or low risk for stroke. 
6. Strategies to minimize interruption or discontinuation of anticoagulant therapy 
should be systematically evaluated, including different in-person or remote follow-up 
patterns and interventions geared at empowering patients. 
7. Interdisciplinary therapeutic strategies for “therapy failures” on oral 
anticoagulation, e.g. patients with an ischaemic stroke on adequate anticoagulation or 
those with severe bleeds, should be developed and evaluated. 
8. Controlled trials of anticoagulation strategies in AF patients with advanced 
kidney disease (MDRD stages IV-V) are urgently needed. 
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9. We recommend high quality research projects on the research on timing of 
recommencing oral anticoagulants after bleeding. 134 
10. The best use of left atrial appendage occlusion devices in clinical practice is not 
well established.135  Evaluation of this technology in patient groups with the potentially 
highest benefit and optimization of post-interventional antithrombotic treatment is 
needed. 
11. Controlled studies on heart rate control comparing beta adrenoceptor-blockers, 
digoxin, and non-dihydropyridine calcium channel blockers as well as heart rate 
targets and their effects on quality of life, cardiac function, and cardiovascular 
outcomes are urgently needed. 
12. Prospective studies evaluating the success of hybrid rhythm control therapy 
combining antiarrhythmic drugs and ablation compared to catheter ablation alone 
seem warranted. Follow-up after catheter ablation for AF should be standardized to 
enable comparison of research results. Evaluation of novel markers for different 
“types” of AF should be integrated into such projects. 
13. Databases of existing trials and cohort studies should be used to propose 
clinical subtypes of AF, e.g. based on imaging, ECG or on blood biomarkers (including 
genetic markers). 
14. Genetic risk variants or genetic risk scores for AF should be examined to see if 
they can help to identify AF or stroke risk prediction, the subtypes of AF, response to 
therapies, or clinical outcomes. 
15. Since clinical trials of AF represent unique research opportunities, we 
encourage the systematic collection of AF covariate data and samples to enable future 
studies on biomarkers and “types of AF”. 
16. Patients should be actively involved in clinical AF research projects. Patients 
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can for example advise on patient information sheets, lay summaries and consent 
forms and help to optimize recruitment strategies, but also contribute to practical 
design aspects. 136  To ensure effective patient involvement, all parties should be clear 
of the role of patient involvement. More information can be found 
(http://www.nets.nihr.ac.uk/ppi; and http://www.invo.org.uk/).   
17. Mechanistic research should be conducted to link genetic variants to AF 
mechanisms, and to reveal novel therapeutic targets. 
18. Long-term research funding is critically necessary to address each of these 
challenges and to ensure the optimal treatment of AF.  
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Table 1: Examples of existing care models for the care of AF patients 
Care model Advantages Disadvantages 
General practitioner Easy access for patients; 
possibility to perform 
initial tests (history, ECG, 
blood sample)  
Limited initial evaluation; 
limited management 
options; lower adherence 
to guidelines137 
Cardiologist/ AF 
subspecialist 
Experience; 
comprehensive evaluation; 
full range of treatment 
options 
Resource demanding; 
initially expensive  
Integrated care of general 
practitioner and internal 
medicine specialist 
More complete assessment 
and management of co-
morbidities 
Limited cardiology-specific 
evaluation and 
management options 
Integrated care of general 
practitioner and 
cardiologist 
More tailored management 
approach using full range 
of treatment options; 
distribution of care across 
healthcare system 
Limited cardiology-specific 
follow-up 
Cardiologist led 
integrated care including 
nurses, allied 
professionals/lifestyle 
specialists 
Full assessment and range 
of treatments; tailored 
follow-up; structured care  
Costs (but possibly cost-
effective) 
Nurse led integrated care Patient-centred care 
approach; efficient and 
possibly cost-effective138 
Education, training and 
monitoring of staff  
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Table 2A: Life style changes that can improve AF management by either improving 
outcomes, reducing the risk of complications, rendering recurrent AF less likely, or 
improving quality of life. 
 
Life style change 
Effect on 
Outcomes and 
complications 
 
recurrent AF and 
quality of life 
Regular physical activity X not known 
Weight reduction not known X 
Low sodium, low fat diet X (by reducing blood 
pressure) 
not known 
Smoking cessation X not known 
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Table 2B. Structured initial care of AF patients 
A. Components of initial care: 
ECG – confirmation of AF139 
Detailed medical history 
mEHRA  symptom assessment 140 
CHA2DS2-VASc stroke risk assessment 141 
Assessment and correction of modifiable bleeding risk factors (e.g. by HASBLED 
score) 142 
Physical examination including blood pressure and body mass index 
Risk factors and comorbidities assessment including heart failure, chronic airways 
disease, dementia, sleep apnoea, renal disease, diabetes, thyroid disease and 
coronary artery disease – requires cardiac imaging (usually echocardiogram) and 
blood sampling 86 
B. Tailored additional evaluation according to the patient: 
Additional diagnostic tests 
Correction of risk factors 
C. Initial management plan 
According to ESC guidelines 
Defined by an AF team representing all relevant expertise 
Advice on life style changes affecting outcomes and AF 
D. Follow-up 
Regular, scheduled follow-ups according to the model of care (see Table 1) 
Assessment of symptoms and patient-reported outcomes (see Section 2, Table 4) 
Heart rate targets (see Section 4) 
Adherence and response to treatment 
Complications of treatment and complications of AF 
Assessment of quality metric targets (see Tables 3 and 4) 
Informed decision on adjustment of therapy 
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Table 3: Quality criteria for management components of atrial fibrillation 
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Table 3.1: Quality criteria for anticoagulant therapy  
Individual risk assessment 
 Assess stroke risk with CHA2DS2-VASc score 
 Assess bleeding risk and minimize bleeding risk factors 
- Control blood pressure 
- Discontinue treatment with non-essential antiplatelet(s)/NSAIDs 
- Counsel patient to reduce alcohol consumption if excessive 
 Check renal function and estimate creatinine clearance prior to deciding on 
anticoagulation therapy 
Guideline adherent OAC prescription 
 CHA2DS2-VASc score ≥2,  OAC recommended 
 Documented decision in patients with CHA2DS2-VASc score = 1 
 If patient is on VKA, achieve high time in therapeutic range (TTR, e.g. > 
65%) 
Decision-making 
Individualized approach to decision making 
 Gauge and follow patient’s desire for involvement in making OAC treatment 
decision (e.g. following input from patient, doctor, or relative) 
Support of anticoagulation therapy 
 OAC-specific information (verbally, pictorially, written)40, 146 
 Check patient understanding of key elements: dose, frequency, with/without 
food, bleeding side effects; result of non-adherence (stroke) 
 check and reinforce knowledge on TIA/stroke alarm symptoms e.g. by 
“FAST” (face, arm, speech, time) and explain need for emergency transfer to stroke 
unit when such symptoms occur 
 Provide written information to reinforce verbal information 
 All information tailored to the patient’s ability to understand and desire for 
information 
Providers of care (see table 2, one option should be available) 
 Physician, nurse, pharmacist, other healthcare professional, ‘expert’ patient, 
combination 
 Nurse led supported by consultant expertise40 
 Supported with software to aid clinical decisions (algorithms)144 
 Intervention for VKA initiation145 
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Table 3.2 Quality criteria for antiarrhythmic drug therapy in AF patients. 
Individual assessment 
 Quantify AF related symptoms (mEHRA score) 147 
 Assess the need for rhythm control on the background of adequate rate 
control 
 Assess concomitant cardiovascular diseases and prior attempts of rhythm 
control to inform choice of AAD 
 Assess 12-lead ECG for signs of conduction or repolarization disturbances 
 Document baseline QT interval, QTc, QRS duration, and QRS abnormalities 
 Check baseline blood levels as needed (thyroid and liver function for 
amiodarone, liver function and creatinine for dronedarone, creatinine and 
estimated creatinine clearance for sotalol, flecainide, and propafenone) 
Guideline adherent prescription and therapy initiation 
 Choose antiarrhythmic drug according to ESC guidelines 
 Prescribe effective dose 
 Monitor ECG during therapy initiation (days 1-3 for flecainide, 
propafenone, and sotalol, week 1 and 2 for dronedarone, week 1 and 4 for 
amiodarone) 
 Monitor blood levels as needed 
Dedicated patient education143 
Provide information on: 
 The main aims of rhythm control therapy (reducing symptoms) 
 The possible need for further procedures (cardioversion, catheter ablation) 
 Possible side effects including proarrhythmia 
 All information tailored to the patient’s ability to understand and desire for 
information 
Once antiarrhythmic drug treatment decision is made 
 Provide clear information on duration of therapy (pill in the pocket, short-
term, long-term) and drug interactions (e.g. anticoagulants) 
 Check patient understanding of key elements: dose, frequency, with/without 
food, result of non-adherence (recurrence of AF) 
 Provide written information to reinforce verbal information 
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Table 3.3 Quality indicators for AF ablation.85 
A. Quality indicators for care in AF ablation centres 
Structured and documented assessment of indications for AF ablation  
- Symptoms (mEHRA score) Prior rhythm control attempts 
- Other therapeutic options (antiarrhythmic drugs, no further rhythm control 
therapy, combination therapy) 
- Likelihood of recurrent AF 
Required infrastructure for AF ablation centres in addition to the general quality 
criteria (See Tables 3.1 and 3.2) 
- Dedicated, adequately equipped electrophysiology laboratory 
- Minimum number of AF ablation procedures per year (over 50) 
- Availability of backup open heart surgery capable of managing 
complications of AF ablation, especially pericardial tamponade 
- Availability of backup anaesthetic support. 
- Data base to track complications over time  
- Regular structured complication conference 
- Standardized patient follow-up program 
B. Quality indicators for AF ablation operators 
Adequately trained and qualified electrophysiologists 
Operators should perform a minimum of 25 AF ablation procedures per year. 
Rate of major complications: defined as complications that prolong hospital stay or 
require intervention. The rate of cardiac tamponade is an important subset of the 
complication rate that should be separately monitored. 
Although efficacy is also important, this parameter is difficult to define as it 
depends on the type and complexity of the patient’s AF, the extent of post-ablation 
monitoring, the definition of success, and the duration of follow-up.  We encourage 
operators to track the recurrence rate of AF, rate of re-ablation, and to assess 
quality of life before and after ablation using dedicated PRO instruments. 
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Table 4 (on line): Relevant biomarkers that have been evaluated to 
identify AF patients at risk for complications. Most markers identify general 
cardiovascular risk and cardiovascular diseases, with the exception of genetic variants 
that are relatively specific for AF. Biomarkers that are specific for AF or for AF-related 
complications seem most promising for further evaluation.  
Biomarker Occurrence/Recurrence 
Complications 
Death Stroke Bleeding 
Cardiovascular stress and cell damage 
Elevated hs-
Troponin 
↑ 148 
↑ (postoperative) 149, 150 
↑ 151-153 ↑ 151-153 ↑ 152, 153 
Elevated BNP 
↑ 99, 100, 154-159 
↑ (postoperative) 160, 161 
↑ 151, 162 ↑ 151, 163-166 X 151 
Inflammation and oxidative stress 
Elevated CRP 
↑ 99, 100, 104, 157, 167-171 
↑ (recurrence after ablation) 171-175 
↑ (recurrence after cardioversion) 176 
X (recurrence after cardioversion) 177 
↑ 178 
↑ 179  
↑ (echo markers of 
thrombus) 180 
  
Elevated GDF-15 X 148 ↑ 181 ↑ 181 ↑ 181 
Kidney function 
High creatinine / 
low eGFR ↑ (recurrence after ablation) 
182 ↑ 183 ↑ 183-187 ↑ 183, 184, 186 
Cystatin C 
↑ 105, 188, 189 
X 190 
↑ 183 ↑ 183 ↑ 183 
Coagulation state 
D-dimer X 99 ↑ 191-193 
↑ 191, 192, 194-196  
↑ (LAA thrombus) 197  
↑ 192 
 
Anaemia 
↑ 189 
↑ (postoperative) 198  
↑ 199  ↑ 187, 200-203 
Common genetic variation 
Chromosome 4q25 
locus, SCN10A, 
SCN5A, KCNE1 
↑ 110, 111, 119, 204-210 
 
 
↑ 111, 211-214 
X (postoperative) 210  
X (Han Chinese) 215 
 
ECG parameters 
PR interval ↑    
P-wave and F-
wave information  
↑ stroke  
↑ recurrence after ablation 
   
↑ = positive association, X = no association ; hs = high-sensitivity. 
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Figure legends 
Figure 1: Roadmap to improve quality of AF services. Shown is a virtuous circle 
relying on four major pillars to improve the quality of AF services for patients. Shared 
decision making, quantifiable quality measures, integration of AF services across 
health care sectors, and the use of stratified approaches to therapy can improve AF 
service quality. They will require continuous evaluation of quality. 
 
Figure 2: Biomarkers may help to define AF subtypes. They can comprise blood and 
tissue based markers as well as electrocardiographic or further objectively determined 
characteristics (e.g. atrial imaging). Both, biomarkers and existing and novel AF 
phenotypes need rigorous validation. 
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